v3.26.3
SEGMENT INFORMATION - Schedule of Reconciliation of Significant Expense Categories (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 10 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Feb. 28, 2025
Feb. 27, 2025
Segment Reporting [Line Items]              
Revenues $ 176,653 $ 179,516 $ 546,428 $ 529,538      
Stock-based compensation     40,320 44,003      
Amortization of acquired intangible assets 12,356 14,322 41,000 42,966      
Acquisition-related expenses 7,384 0 7,384 0      
Changes in the fair value of contingent consideration (14,430) 625 (15,044) (2,407)      
Legal judgment 0 (23,148) 0 (23,148)      
Legal settlement 0 0 0 7,000      
Impairment of acquired IPR&D 0 25,866 0 25,866      
Total operating expenses 154,381 173,154 512,987 512,687      
Total other income (loss), net 6,542 3,162 2,926 (548)      
Income before income taxes 28,814 9,524 36,367 16,303      
Income tax expense (293) (4,092) (277) (10,906)      
Net income 28,521 5,432 36,090 5,397      
Divestiture-related expenses 705 0 6,636 0      
Separation costs 611 0 611 0      
Employee termination benefit charges   3,700   3,700      
Accelerated depreciation expense 6,500 5,500 6,500 5,500      
Pacira CryoTech, Inc, and iovera°              
Segment Reporting [Line Items]              
Divestiture-related expenses 700   6,600        
Separation costs 600   600        
Transaction bonus 2,200   2,200        
Viatris Inc.              
Segment Reporting [Line Items]              
Acquisition-related expenses 7,400   7,400        
GQ Bio Therapeutics GmbH              
Segment Reporting [Line Items]              
Acquisition-related expenses     2,200        
Percentage of voting interests acquired           81.00%  
Key employee holdback agreement             $ 7,800
Key employee holdback agreement payment period         3 years    
Key employee holdback recognition year one             50.00%
Key employee holdback recognition year two             30.00%
Key employee holdback recognition year three             20.00%
Payment for achievement of regulatory milestone 600 1,200 2,100 2,600      
GQ Bio Therapeutics GmbH | GQ Bio Therapeutics GmbH              
Segment Reporting [Line Items]              
Percentage of voting interests acquired           81.00%  
Reportable Segment              
Segment Reporting [Line Items]              
Revenues 176,653 179,516 546,428 529,538      
Adjusted cost of goods sold 35,489 32,772 112,614 98,025      
Adjusted research and development 23,931 22,489 76,346 70,276      
Adjusted selling and marketing 47,844 58,471 158,128 165,006      
Adjusted general and administrative 25,882 23,180 80,741 70,020      
Stock-based compensation 11,823 13,978 40,320 44,003      
Amortization of acquired intangible assets 12,356 14,322 41,000 42,966      
Acquisition-related expenses 7,384 0 7,384 0      
Divestiture-related and acquisition-related expenses 4,102 871 11,498 4,831      
Changes in the fair value of contingent consideration (14,430) 625 (15,044) (2,407)      
Restructuring charges and other 0 3,728 0 10,249      
Legal judgment 0 (23,148) 0 (23,148)      
Legal settlement 0 0 0 7,000      
Impairment of acquired IPR&D 0 25,866 0 25,866      
Total operating expenses 154,381 173,154 512,987 512,687      
Total other income (loss), net 6,542 3,162 2,926 (548)      
Income before income taxes 28,814 9,524 36,367 16,303      
Income tax expense (293) (4,092) (277) (10,906)      
Net income $ 28,521 $ 5,432 $ 36,090 $ 5,397